Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Hedger G et al. | Free Energy Landscape of Lipid Interactions with Regulatory Binding Sites on the Transmembrane Domain of the EGF Receptor. | 2016 | J Phys Chem B | pmid:27109430 |
Kawashima N et al. | Induction of Glycosphingolipid GM3 Expression by Valproic Acid Suppresses Cancer Cell Growth. | 2016 | J. Biol. Chem. | pmid:27539856 |
Palomo AG et al. | Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications. | 2016 | Clin. Exp. Metastasis | pmid:27449755 |
Fedoryszak-Kuśka N et al. | Glucosylceramide synthase inhibitors D-PDMP and D-EtDO-P4 decrease the GM3 ganglioside level, differ in their effects on insulin receptor autophosphorylation but increase Akt1 kinase phosphorylation in human hepatoma HepG2 cells. | 2016 | Acta Biochim. Pol. | pmid:27172362 |
Yoshinaga A et al. | NEU3 inhibitory effect of naringin suppresses cancer cell growth by attenuation of EGFR signaling through GM3 ganglioside accumulation. | 2016 | Eur. J. Pharmacol. | pmid:27105818 |
Winner LK et al. | A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome. | 2016 | Hum. Gene Ther. | pmid:26975339 |
Gentilini MV et al. | The tumor antigen N-glycolyl-GM3 is a human CD1d ligand capable of mediating B cell and natural killer T cell interaction. | 2016 | Cancer Immunol. Immunother. | pmid:26969612 |
Gabri MR et al. | Racotumomab for treating lung cancer and pediatric refractory malignancies. | 2016 | Expert Opin Biol Ther | pmid:26903265 |
Wang H et al. | Early growth and development impairments in patients with ganglioside GM3 synthase deficiency. | 2016 | Clin. Genet. | pmid:26649472 |
Xu F et al. | Lipid-Mediated Targeting with Membrane-Wrapped Nanoparticles in the Presence of Corona Formation. | 2016 | ACS Nano | pmid:26720275 |